Scindeks Asistent Scindeks Asistent — sistem za ozbiljne časopise i one koji to žele da postanu
Vol. 43 Br. 4 (2024)
Vol. 43 Br. 4 (2024)

Da li farmakogenetika ima uticaj na ishod lečenja odraslih pacijenata sa akutnom mijeloidnom leukemijom lečenih primenom citarabina i antraciklina? Srpsko iskustvo

DOI: 10.5937/jomb0-47459
Zlatko Pravdić
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade
Marijana Virijević
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Mirjana Mitrović
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Nikola Pantić
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade
Nikica Sabljić
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade
Đorđe Pavlović
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
Irena Marjanović
Zoran Bukumirić
Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ana Vidović
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ljubomir Jaković
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade
Sonja Pavlović
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
Nada Suvajdžić
Clinic of Hematology, University Clinical Centre of Serbia, Belgrade; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Vladimir Gasic
Institute of Molecular Genetics and Genetic Engineering image/svg+xml
PDF (engleski)

Objavljeno

2024-04-26

Sekcija

Original paper

Sažetak

Uvod. Indukciona terapija zasnovana na citarabinu i antraciklinu standard je lečenja novodijagnostikovanih odraslih pacijenata sa akutnom mijeloidnom leukemijom (AML). Ishodi lečenja među obolelima od AML značajno se razlikuju. Ove razlike bi se delimično mogle objasniti genetičkim varijabilitetom metaboličkih puteva citarabina i antraciklina. Cilj ovog istraživanja bilo je ispitivanje uticaja varijanti u farmakogenima SLC29A1, DCK, ABCB1, GSTM1 i GSTT1, kao i laboratorijskih i parametara vezanih za AML na ishode lečenja odraslih bolesnika sa AML.    

Metode. Ukupno 100 bolesnika sa AML je uključeno u studiju. Farmakogenetičke varijante SLC29A1 rs9394992, DCK rs12648166, ABCB1 rs2032582 i delecije gena GSTM1 i GSTT1 određivane su metodologijom zasnovanom na PCR-u, analizom fragmenata i direktnim sekvenciranjem. Korišćene su metode deskriptivne i analitičke statistike. Analiza preživljavanja je sprovedena prema Kaplan-Majerovom metodu upotrebom Log-Rank testa.

Rezultati. Ovo je prva farmakogenetička studija odraslih bolesnika sa AML u srpskoj populaciji. Varijante u genima SLC29A1, DCK, ABCB1, GSTT1 i GSTM1 nisu uticale na ishode lečenja u našoj kohorti obolelih od AML, samostalno ili u međusobnim kombinacijama. Međutim, postizanje kompletne remisije bolesti istaklo se kao nezavisni prediktor ishoda lečenja.

Zaključak. Prilikom farmakogenetičkih istraživanja neophodno je razmotriti jedinstveni genetički profil ispitivane populacije. Kako su farmakogenetički podaci o AML u evropskim populacijama oskudni, naši rezultati doprinose proširenju saznanja u ovoj oblasti i ukazuju na značaj primena tehnika sekvenciranja nove generacije u cilju otkrivanja posebnih farmakogenetičkih markera kod obolelih od AML u evropskim populacijama.

Ključne reči

Array
Array
Array
Array
DOI: 10.5937/jomb0-47459

Reference

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Preuzimanja

Podaci o preuzimanju još nisu dostupni.